[Treatment of Parkinson's syndrome with L-dopa].
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001463:Barbiturates / Q000627:therapeutic use; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D004298:Dopamine / Q000096:biosynthesis; D004336:Drug Antagonism; D004344:Drug Incompatibility; D004357:Drug Synergism; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D006948:Hyperkinesis / Q000139:chemically induced; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000601:surgery; D011736:Pyridoxine / Q000627:therapeutic use; D012110:Reserpine / Q000627:therapeutic use; D013238:Stereotaxic Techniques; D014149:Tranquilizing Agents / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000892:Anti-Infective Agents, Urinary; D000959:Antihypertensive Agents; D001463:Barbiturates; D008996:Monoamine Oxidase Inhibitors; D010276:Parasympatholytics; D014149:Tranquilizing Agents; D004295:Dihydroxyphenylalanine; D012110:Reserpine; D011736:Pyridoxine; D004298:Dopamine
Behandlung des Parkinson-Syndroms mit L-Dopa.